Connect with us

Technology

VODAFONE GROUP PUBLIC LIMITED COMPANY LAUNCHES CASH TENDER OFFERS FOR U.S. DOLLAR NOTES DUE 2025 AND 2028

Published

on

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON RESIDENT AND/OR LOCATED IN, ANY JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL

NEWBURY, England, Feb. 5, 2025 /PRNewswire/ — Vodafone Group Plc (“Vodafone” or the “Company”) announces the launch of its offers to purchase for cash in two concurrent, but separate offers, any and all of its outstanding (i) 4.125% Notes due May 2025 (the “Fixed Price Notes”), of which $734,128,000 is outstanding, and (ii) 4.375% Notes due May 2028 (the “Fixed Spread Notes” and, together with the Fixed Price Notes, the “Notes”), of which $575,122,000 is outstanding, upon the terms of, and subject to the conditions in, the offer to purchase dated February 5, 2025 (the “Offer to Purchase”) and the accompanying notice of guaranteed delivery (the “Notice of Guaranteed Delivery” and, together with the Offer to Purchase, the “Tender Offer Documents”).

Each offer to purchase each series of Notes is referred to herein as an “Offer” and the offers to purchase the Notes as the “Offers.” Capitalised terms not otherwise defined in this announcement have the same meaning as assigned to them in the Offer to Purchase.

Holders are advised to read carefully the Tender Offer Documents for full details of, and information on the procedures for participating in, the Offers. All documentation relating to the Offers, including the Tender Offer Documents, together with any updates, are available at the following website: https://deals.is.kroll.com/vodafone-usd.

The following tables set forth certain terms of the Offers:

Title of Security

CUSIP / ISIN

Outstanding
Principal
Amount

Reference U.S.
Treasury Security

Bloomberg
Reference Page(1)

Fixed Spread
(basis points)

Fixed Price(2)

4.125% Notes due May
2025

92857WBJ8 /
US92857WBJ80

$734,128,000

N/A

N/A

N/A

$1,000

4.375% Notes due May
2028

92857WBK5/
US92857WBK53

$575,122,000

4.25% U.S.
Treasury due
January 15, 2028

FIT1

20

N/A

(1)  The page on Bloomberg from which the Dealer Managers will quote the bid-side price of the applicable Reference U.S. Treasury Security.

(2)  Per $1,000 in principal amount of Fixed Price Notes (as defined below) validly tendered and accepted for purchase.

 

All Notes accepted in the Offers will be cancelled and retired by the Company.

Purpose of the Offers

The Offers, the Concurrent Non-U.S. Tender Offers (as defined below) and the 2025 Notes Redemption (as defined below) are being undertaken to, among other things, proactively manage the Company’s outstanding debt portfolio, with a focus on the Company’s near-dated maturities. 

Concurrent Non-U.S. Tender Offers

Concurrently with the launch of the Offers, the Company has commenced cash tender offers for any and all of its outstanding €1,000,000,000 1.875% Notes due 2025, €1,000,000,000 1.125% Notes due 2025, €1,750,000,000 2.200% Notes due 2026, €750,000,000 0.900% Notes due 2026, €500,000,000 1.50% Notes due 2027, £250,000,000 5.625% Notes due 2025, CHF 175,000,000 0.625% Notes due 2027, AUD 450,000,000 4.200% Notes due 2027, NOK 850,000,000 3.215% Notes due 2025, NOK 850,000,000 3.115% Notes due 2027, NOK 500,000,000 2.925% Notes due 2027, HKD 455,000,000 2.850% Notes due 2027 and HKD 1,115,000,000 2.640% Notes due 2027 (the “Concurrent Non-U.S. Tender Offers”).

The Concurrent Non-U.S. Tender Offers are not being made, and will not be made, directly or indirectly, in or into the United States or to, or for the account or benefit of, any U.S. Person (as defined in Regulation S under the U.S. Securities Act of 1933).

2025 Notes Redemption

Concurrently with the launch of the Offers, the Company is issuing a notice of redemption in respect of any Fixed Price Notes not purchased by the Company in the Offers (the “2025 Notes Redemption”), at a price equal to the greater of (1) 100% of the principal amount of such Notes plus accrued and unpaid interest to the date of redemption, if any, and (2) the sum of the present values of the remaining scheduled payments of principal and interest on such Notes (excluding any portion of such payments of interest accrued as of the date of redemption) discounted to the date of redemption on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the sum of (i) the adjusted treasury rate (as defined in the prospectus supplement dated May 23, 2018 relating to the Fixed Price Notes) plus (ii) 20 basis points, plus accrued and unpaid interest, if any, to the date of redemption.

Purchase Price Consideration

Upon the terms and subject to the conditions set forth in the Tender Offer Documents, Holders of the Notes who validly tender and do not validly withdraw the Notes at or prior to the Expiration Time or the Guaranteed Delivery Date pursuant to the Guaranteed Delivery Procedures, and whose Notes are accepted for purchase by the Company, will receive the Purchase Price Consideration for each $1,000 principal amount of the Notes, which will be payable in cash.

The Purchase Price Consideration for each $1,000 principal amount of Fixed Price Notes validly tendered, not validly withdrawn, and accepted by us pursuant to the relevant Offer will be the Fixed Price specified in the table above.

The Purchase Price Consideration for each $1,000 principal amount of Fixed Spread Notes validly tendered, not validly withdrawn, and accepted by us pursuant to the relevant Offer will be calculated at the Price Determination Time and will be determined in accordance with standard market practice, as described below, using the sum of (such sum, the “Offer Yield”):

(i)  the reference yield, as calculated by the Dealer Managers in accordance with standard market practice, that corresponds to the bid-side price of the Reference U.S. Treasury Security in the table above for the Notes appearing at the Price Determination Time on the Bloomberg Reference Page specified in the table above for the Notes (or any other recognized quotation source selected by Vodafone in consultation with the Dealer Managers if such quotation report is not available or manifestly erroneous) (such reference yield, the “Reference Yield”), plus

(ii)  the Fixed Spread specified in the table above.

Subject to the terms and conditions described in the Tender Offer Documents, the Price Consideration for each $1,000 principal amount of the Fixed Spread Notes accepted by us pursuant to the relevant Offer will be determined in accordance with standard market practice as described by the formula set forth in Annex A-1 to the Offer to Purchase, and will equal (i) the present value on the Settlement Date of $1,000 principal amount of such Notes due on the scheduled maturity date of such Notes and all scheduled interest payments on such Notes to be made from (but excluding) the Settlement Date up to (and including) such scheduled maturity date, discounted to the Settlement Date at a discount rate equal to the Offer Yield, minus (ii) the Accrued Interest per $1,000 principal amount of the Fixed Spread Notes; with the total amount being rounded to the nearest cent per $1,000 principal amount of such Notes.

Vodafone will issue a press release specifying the Purchase Price Consideration for the Fixed Spread Notes as soon as reasonably practicable after the determination thereof by the Dealer Managers.

Accrued Interest

In addition to the Purchase Price Consideration, Holders whose Notes are accepted for purchase will be paid the Accrued Interest thereon. Interest will cease to accrue on the Settlement Date for all Notes accepted in the Offers. For avoidance of doubt, interest will cease to accrue on the Settlement Date for all Notes accepted in the Offers, including Notes that are delivered pursuant to the Guaranteed Delivery Procedures. All Notes accepted in the Offers will be canceled and retired by Vodafone.

Key Dates, Offer Period and Results

Holders of the Notes should note the following dates relating to the Offers:

Date

Calendar Date

Launch Date

February 5, 2025.

 

Price Determination Time

 

At or around 11:00 a.m., New York City time, on February 11, 2025, unless
extended or earlier terminated by the Company in its sole and absolute
discretion, subject to applicable law.

 

Withdrawal Deadline

 

5:00 p.m., New York City time, on February 11, 2025, unless extended or
earlier terminated by the Company in its sole and absolute discretion, subject
to applicable law.

 

Expiration Time

 

5:00 p.m., New York City time, on February 11, 2025, unless extended or
earlier terminated by the Company in its sole and absolute discretion, subject
to applicable law.

 

Results Announcement Date

 

The first business day after Expiration Time, February 12, 2025.

 

Guaranteed Delivery Date

 

5:00 p.m., New York City time, on February 12, 2025.

 

Settlement Date

 

In respect of accepted Notes that are delivered at or prior to the Expiration
Time, the Company expects the Settlement Date to occur on the third
business day after the Expiration Time, February 14, 2025. 

 

Guaranteed Delivery

 

Settlement Date

 

 

In respect of accepted Notes that are delivered pursuant to the Guaranteed

 

Delivery Procedures, the Company expects the Guaranteed Delivery
Settlement Date to occur on the second business day after the Guaranteed
Delivery Date, February 14, 2025.

 

The deadlines set by any intermediary and The Depository Trust Company (“DTC) for participation in the Offers may be earlier than the relevant deadline specified above. The acceptance of Notes for purchase is conditional on the satisfaction of the conditions of the Offers as provided in “Description of the Offers—Conditions to the Offers” in the Offer to Purchase.

The Company has retained Merrill Lynch International and Barclays Capital Inc. as Dealer Managers and Kroll Issuer Services Limited as Tender and Information Agent (the “Tender and Information Agent”) for the purposes of the Offers.

Questions regarding procedures for tendering Notes may be directed to the Tender and Information Agent at +44 20 7704 0880 (London) or by email to vodafone-usd@is.kroll.com, Attention: Owen Morris. Questions regarding the Offers may be directed to Merrill Lynch International at +1 (888) 292-0070 (toll free), +1 (980) 387-3907 or +44 207 996 5420 (in London) or by email to DG.LM-EMEA@bofa.com and to Barclays Capital Inc. at +1 (800) 438-3242 (toll free), +1 (212) 528-7581 or +44 203 134 8515 (in London) or by email to us.lm@barclays.com.

This announcement is for informational purposes only and does not constitute an offer to buy, or a solicitation of an offer to sell, any security. No offer, solicitation, or sale will be made in any jurisdiction in which such an offer, solicitation, or sale would be unlawful. The Offers are only being made pursuant to the Offer to Purchase. Holders of the Notes are urged to carefully read the Offer to Purchase before making any decision with respect to the Offers.

The distribution of this announcement in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required by each of the Company, the Dealer Managers and the Tender and Information Agent to inform themselves about and to observe any such restrictions.

Offer and Distribution Restrictions

Italy

None of the Offers, this announcement, the Offer to Purchase or any other document or materials relating to the Offers has been or will be submitted to the clearance procedures of the Commissione Nazionale per le Società e la Borsa (“CONSOB”) pursuant to Italian laws and regulations. The Offers are being carried out in the Republic of Italy (“Italy“) as an exempt offer pursuant to article 101-bis, paragraph 3-bis of the Legislative Decree No. 58 of February 24, 1998, as amended (the “Financial Services Act”) and article 35-bis, paragraph 4 of CONSOB Regulation No. 11971 of May 14, 1999, as amended. Holders or beneficial owners of the Notes that are resident or located in Italy can tender Notes for purchase in the Offers through authorised persons (such as investment firms, banks or financial intermediaries permitted to conduct such activities in Italy in accordance with the Financial Services Act, CONSOB Regulation No. 20307 of February 15, 2018, as amended from time to time, and Legislative Decree No. 385 of September 1, 1993, as amended) and in compliance with any other applicable laws and regulations and with any requirements imposed by CONSOB or any other Italian authority.

Each intermediary must comply with the applicable laws and regulations concerning information duties vis-à-vis its clients in connection with the Notes and/or the Offers.

United Kingdom

The communication of this announcement and the Offer to Purchase and any other documents or materials relating to the Offers is not being made by and such documents and/or materials have not been approved by an “authorised person” for the purposes of section 21 of the Financial Services and Markets Act 2000 (“FSMA 2000”). Accordingly, such documents and/or materials are not being distributed to, and must not be passed on to, the general public in the United Kingdom. The communication of such documents and/or materials is exempt from the restriction on financial promotions under section 21(1) of the FSMA on the basis that it is only directed at and may only be communicated to: (1) persons who are outside of the United Kingdom; (2) investment professionals falling within the definition contained in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Financial Promotion Order”); (3) those persons who are existing members or creditors of the Company or other persons falling within Article 43(2) of the Financial Promotion Order; or (4) any other persons to whom such documents and/or materials may lawfully be communicated in accordance with the Financial Promotion Order (all such persons together referred to as “relevant persons”). This announcement, the Offer to Purchase and any other documents or materials relating to the Offers are only available to relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

France

The Offers are not being made, directly or indirectly, and neither this announcement, the Offer to Purchase nor any other document or material relating to the Offers has been or shall be distributed, to the public in the Republic of France other than to qualified investors as defined in Article 2(e) of the Regulation (EU) 2017/1129 (the “Prospectus Regulation”). Neither this announcement, the Offer to Purchase nor any other document or materials relating to the Offers have been or will be submitted for clearance to nor approved by the Autorité des Marchés Financiers.

Belgium

Neither this announcement, the Offer to Purchase nor any other brochure, documents or materials relating to the Offers has been, or will be, submitted or notified to, or approved or recognized by, the Belgian Financial Services and Markets Authority (“Autorité des services et marchés financiers”/”Autoriteit voor Financiële Diensten en Markten”). In Belgium, the Offers do not constitute a public offering within the meaning of Articles 3, §1, 1° and 6, §1 of the Belgian Law of April 1, 2007 on public takeover bids (“loi relative aux offres publiques d’acquisition”/”wet op de openbare overnamebiedingen”), as amended or replaced from time to time. Accordingly, the Offers may not be, and is not being advertised, and this announcement, the Offer to Purchase, as well as any brochure, or any other material or document relating thereto (including any memorandum, information circular, brochure or any similar document) may not, has not and will not be distributed or made available, directly or indirectly, to any person located and/or resident within Belgium, other than to “qualified investors” (“investisseurs qualifiés”/”qekwalificeerde belegge”), within the meaning of Article 2(e) of the Prospectus Regulation acting on their own account. Insofar as Belgium is concerned, the Offers are made only to qualified investors, as this term is defined above. Accordingly, the information contained in this announcement, the Offer to Purchase or in any brochure or any other document or material relating thereto may not be used for any other purpose or disclosed or distributed to any other person in Belgium.

General

This announcement does not constitute an offer to buy or the solicitation of an offer to sell Notes (and tenders of Notes in the Offers will not be accepted from Holders) in any circumstances in which such offer or solicitation or acceptance is unlawful. In those jurisdictions where the securities, blue sky or other laws require the Offer to be made by a licensed broker or dealer and any Dealer Manager or any of the Dealer Managers’ affiliates is such a licensed broker or dealer in any such jurisdiction, the Offers shall be deemed to be made by such Dealer Manager or such Dealer Manager’s affiliate, as the case may be, on behalf of the Company in such jurisdiction.

Each tendering Holder participating in the Offers will be deemed to give certain representations in respect of the jurisdictions referred to above and generally as set out in the section titled “Description of the Offers—Procedures for Tendering Notes—Other Matters” in the Offer to Purchase. Any tender of Notes for purchase pursuant to the Offers from a Holder that is unable to make these representations will not be accepted. Each of the Company, the Dealer Managers and the Tender and Information Agent reserves the right, in its sole and absolute discretion, to investigate, in relation to any tender of Notes for purchase pursuant to the Offers, whether any such representation given by a Holder is correct and, if such investigation is undertaken and as a result the Company determines (for any reason) that such representation is not correct, such tender shall not be accepted.

Forward-Looking Information

This announcement contains certain forward-looking statements which reflect the Company’s intent, beliefs or current expectations about the future and can be recognised by the use of words such as “expects,” “will,” “anticipate,” or words of similar meaning. These forward-looking statements are not guarantees of any future performance and are necessarily estimates reflecting the best judgment of the senior management of the Company and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. As a consequence, these forward-looking statements should be considered in light of various important factors that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements, which include, without limitation, the risk factors set forth in the Offer to Purchase. The Company cannot guarantee that any forward-looking statement will be realised, although it believes it has been prudent in its plans and assumptions. Achievement of future results is subject to risks, uncertainties and assumptions that may prove to be inaccurate. Should known or unknown risks or uncertainties materialise, or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated, estimated or projected. The Company undertakes no obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances or to reflect the occurrence of unanticipated events, except as required by applicable law.

View original content:https://www.prnewswire.com/news-releases/vodafone-group-public-limited-company-launches-cash-tender-offers-for-us-dollar-notes-due-2025-and-2028-302368634.html

SOURCE Vodafone Group Plc

Continue Reading

Technology

Amid Rising Costs and Surgical Disruptions in ASCs, NorthStar Anesthesia Strengthens Focus on ASC Partnerships

Published

on

By

With 17 new ASC partnerships nationwide to date in 2026, NorthStar Anesthesia emphasizes proactive patient assessment, reliable staffing, and clinical consistency to help surgery centers reduce preventable cancellations and maximize surgical capacity.

IRVING, Texas, Oct. 23, 2026 /PRNewswire/ — As ambulatory surgery centers (ASCs) face mounting financial pressures, staffing challenges, and increasingly complex patient needs, anesthesia has emerged as a critical partner in their ability to operate efficiently and sustainably. NorthStar Anesthesia is addressing these challenges through a dedicated ASC model designed to reduce preventable case cancellations, improve surgical throughput, and help centers make the most of their existing operating room capacity.

NorthStar celebrates 17 new ASC partnerships nationwide to date in 2026.

“The challenge for ASCs today isn’t simply finding anesthesia coverage. It’s ensuring that coverage translates into reliable surgical capacity,” said Cindy Myers, Vice President of ASC Operations at NorthStar Anesthesia. “When cases are cancelled unnecessarily or operating rooms aren’t running as planned, the impact extends well beyond the anesthesia department. Our focus is on helping centers address those challenges systematically, so they can deliver more consistent care and operate more efficiently.”

Reducing Preventable Cancellations Through Better Preparation

One of the most significant opportunities to improve ASC performance lies in the preoperative process. When potential anesthesia concerns are not identified until the day of surgery, patients may face unexpected cancellations, surgeons lose valuable operating time, and centers absorb the cost of unused capacity.

NorthStar addresses this challenge through ASC-specific pre-anesthesia testing (PAT) guidelines and standardized clinical protocols designed to identify potential issues earlier, facilitate appropriate patient optimization, and support consistent decision-making across the surgical process.

“In ambulatory surgery, the decisions made before the patient arrives are often just as important as those made in the operating room,” said Gajan Mahendran, MD, Vice President of Physician Services at NorthStar Anesthesia. “A consistent, evidence-based approach to preoperative assessment helps us identify risks earlier, determine which patients are appropriate for the ASC setting, and address potential barriers to surgery in advance. That means fewer last-minute surprises and a better experience for patients, surgeons, and facilities.”

Aligning Anesthesia Resources With Surgical Demand

Alongside clinical challenges, ASCs are navigating a changing economic environment. In a recent Becker’s ASC Review interview, NorthStar CEO Adam Spiegel noted that approximately 80% of ASCs in NorthStar’s network now require anesthesia stipends, compared with just 10% to 15% before the pandemic.

As anesthesia costs rise, ensuring that staffing levels align with actual surgical demand has become increasingly important. NorthStar works with ASC partners to develop staffing models that reflect each facility’s case mix, surgical volume, and operating requirements. “Adding anesthesia resources doesn’t automatically improve performance if those resources aren’t aligned with the center’s surgical volume,” Myers said. “We work closely with our partners to understand their schedules, case mix, and operational needs so we can build a model that supports both reliable access to care and financial sustainability.”

Combining National Resources With Local Clinical Expertise

As ASCs take on a greater share of surgical procedures, the demands placed on anesthesia providers are becoming more complex. Smaller or locally managed anesthesia groups may face challenges maintaining consistent coverage, recruiting clinicians, or investing in standardized clinical and operational processes.

NorthStar’s model combines local clinical leadership with national recruiting capabilities, dedicated ASC operations expertise, and established quality guidelines. This infrastructure helps support continuity of care, consistent clinical practices, and the flexibility to respond to changes in surgical demand.

The approach is reflected in NorthStar’s expanding ASC partnerships.  To date in 2026 alone, NorthStar has added 17 ASC partnerships, including CarePlex Orthopaedic Ambulatory Surgery Center in Norfolk, Virginia; Stony Point Surgery Center and West Creek Surgery Center, both part of MedRVA Healthcare in Richmond, Virginia; an Orthopedic Surgery Center in Wisconsin; Eye Surgery Center of Homewood in Homewood, Alabama; and The Toledo Clinic ASC in Toledo, Ohio.

These partnerships reflect the growing importance of anesthesia providers that can address both the clinical and operational needs of outpatient surgery centers.

To learn more and to request a confidential anesthesia program assessment, please contact James Bagliani, Director of Business Development, NorthStar Anesthesia at james.bagliani@northstaranesthesia.com. 

About NorthStar Anesthesia

NorthStar Anesthesia is a company of caregivers, founded by an anesthesiologist and a Certified Registered Nurse Anesthetist (CRNA). With more than 4,000 anesthesiologists and CRNAs under its banner, NorthStar partners with more than 280 healthcare client sites across more than 20 states and counting to deliver a more productive and efficient model of anesthesia care. Its care team approach focuses on the provision of high-quality care while measurably improving operating room performance.

Media Contact: James Bagliani, Director of Business Development, NorthStar Anesthesia james.bagliani@northstaranesthesia.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/amid-rising-costs-and-surgical-disruptions-in-ascs-northstar-anesthesia-strengthens-focus-on-asc-partnerships-302918226.html

SOURCE NorthStar Anesthesia

Continue Reading

Technology

Dimethylaminopropylamine Market to Reach USD 731.9 Million by 2035 on Surfactant and Epoxy Demand, Credence Research Finds

Published

on

By

LONDON, Oct. 23, 2026 /PRNewswire/ — Credence Research Inc. has added the “Dimethylaminopropylamine Market – Growth, Share, Opportunities & Competitive Analysis, 2025–2035” study to its market intelligence portfolio. The report examines market value, segmentation, demand drivers, regional dynamics, competition and recent industry developments.

The dimethylaminopropylamine (DMAPA) market was valued at USD 452.6 million in 2025 and is projected to reach USD 731.9 million by 2035, representing a 4.92% compound annual growth rate over 2025–2035, according to Credence Research. The firm estimates 2026 revenue at USD 474.3 million. Asia Pacific accounted for the largest modeled geographic share at 44.0% in 2025, while Asia Pacific is projected to grow fastest at 5.88% annually. Market sizes, regional shares and segment shares are Credence Research estimates rather than independently audited industry totals.

Key Takeaways

The market is forecast to increase from USD 452.6 million in 2025 to USD 731.9 million by 2035, with a reported CAGR of 4.92%.Asia Pacific led the modeled 2025 geography with 44.0%; Asia Pacific has the fastest forecast geographic growth of 5.88%.By application, Surfactants accounted for 61.0% of modeled 2025 value, while Epoxy curing agents is forecast to grow at 5.66% a year.By end-use industry, Personal care and cosmetics accounted for 44.0% of modeled 2025 value, while Paints, coatings and composites is forecast to grow at 5.61% a year.The market definition excludes adjacent product or transaction value where that spending is outside the report’s measured scope.

Scope & Segmentation – Dimethylaminopropylamine Market

The study values sales of 3-(dimethylamino)-1-propylamine, an amine intermediate produced from dimethylamine and acrylonitrile. Included uses span betaine and amine-oxide surfactants, epoxy curing agents, polyurethane catalysts, water treatment chemicals, agrochemical intermediates and lubricant additives. Finished surfactants, coatings and other downstream products are excluded from the DMAPA revenue estimate.

By application: Surfactants (betaines and amine oxides); Epoxy curing agents; Polyurethane catalysts; Water treatment chemicals; Agrochemical intermediates; Fuel and lubricant additives; Others.By end-use industry: Personal care and cosmetics; Home care and institutional cleaning; Paints, coatings and composites; Water treatment; Agriculture; Automotive and lubricants.By geography: Asia Pacific; Europe; North America; Latin America; Middle East and Africa.

Read the complete report and request a sample: https://www.credenceresearch.com/report/dimethylaminopropylamine-market 

Why This Report Matters

The study distinguishes a narrowly defined revenue pool from adjacent activity that can inflate comparisons between research estimates. This helps strategy teams compare suppliers, customer budgets and product categories on a consistent basis.The base-year segment mix identifies where current purchasing is concentrated, while the modeled faster-growing categories help evaluate investment timing and market entry.Geographic shares are proprietary estimates; company and regulatory announcements are used to explain demand mechanisms, not to independently verify global market totals.

Market Overview
The study values sales of 3-(dimethylamino)-1-propylamine, an amine intermediate produced from dimethylamine and acrylonitrile. Included uses span betaine and amine-oxide surfactants, epoxy curing agents, polyurethane catalysts, water treatment chemicals, agrochemical intermediates and lubricant additives. Finished surfactants, coatings and other downstream products are excluded from the DMAPA revenue estimate.

DMAPA is a building block for cocamidopropyl betaine and related surfactants used in shampoos, body washes and dishwashing products. Producers serving consumer brands require consistent quality and supply, so the largest application tends to support repeat orders rather than episodic equipment-style purchases.

The outlook reflects expected changes in customer adoption, procurement, technology and regulation. It should be read as a modeled scenario, not as a guarantee of sales or company performance.

Key Attributes

Attribute

Details

Base year

2025

Historical reference

2018–2025

2025 market size

USD 452.6 million

2026 estimate

USD 474.3 million

2035 market forecast

USD 731.9 million

Reported CAGR

4.92% (2025–2035)

Geographic scope

Global

Primary source

https://www.credenceresearch.com/report/dimethylaminopropylamine-market

Segmentation

By application
The study divides this category into surfactants (betaines and amine oxides); epoxy curing agents; polyurethane catalysts; water treatment chemicals; agrochemical intermediates; fuel and lubricant additives; others. Surfactants led the 2025 value mix with 61.0%. Epoxy curing agents is the fastest-growing modeled subsegment at 5.66% a year. These shares represent Credence Research model outputs, not audited supplier sales.

By end-use industry
The study divides this category into personal care and cosmetics; home care and institutional cleaning; paints, coatings and composites; water treatment; agriculture; automotive and lubricants. Personal care and cosmetics led the 2025 value mix with 44.0%. Paints, coatings and composites is the fastest-growing modeled subsegment at 5.61% a year. These shares represent Credence Research model outputs, not audited supplier sales.

Market Growth Drivers

Mild cleansing formulas sustain high-volume demand
DMAPA is a building block for cocamidopropyl betaine and related surfactants used in shampoos, body washes and dishwashing products. Producers serving consumer brands require consistent quality and supply, so the largest application tends to support repeat orders rather than episodic equipment-style purchases.

Epoxy hardeners provide a faster-growth outlet
DMAPA-based amidoamines are used in epoxy curing systems for floors, protective coatings and composite applications. Wind blade production and industrial maintenance provide additional demand. The report models epoxy curing agents as the fastest-growing application, although their value starts below surfactants.

Capacity integration shapes producer economics
The chemical route depends on dimethylamine and acrylonitrile, making feedstock access and energy costs important. Integrated producers can manage these inputs and purity requirements more directly, while regional buyers value dependable supply and local technical support.

Regional Analysis
Asia Pacific held 44.0% of modeled 2025 revenue, while Asia Pacific is expected to record the fastest regional growth at 5.88%. The allocation follows the study’s defined buyer or provider-revenue scope.

Asia Pacific
Asia Pacific represented 44.0% of modeled 2025 market value. China hosts extensive betaine and epoxy manufacturing and new intermediate capacity. Regional performance also depends on local regulation, industrial investment and purchasing conditions.

Europe
Europe represented 23.0% of modeled 2025 market value. Specialty formulations and high-purity specifications sustain demand. Regional performance also depends on local regulation, industrial investment and purchasing conditions.

North America
North America represented 21.0% of modeled 2025 market value. Personal care, coating and water treatment buyers support a mature market. Regional performance also depends on local regulation, industrial investment and purchasing conditions.

Latin America
Latin America represented 7.0% of modeled 2025 market value. Brazilian and Mexican cleaning and personal care production expands. Regional performance also depends on local regulation, industrial investment and purchasing conditions.

Middle East and Africa
Middle East and Africa represented 5.0% of modeled 2025 market value. Industrial chemicals and water treatment provide emerging outlets. Regional performance also depends on local regulation, industrial investment and purchasing conditions.

Market Challenges

Input prices and possible overcapacity
Changes in acrylonitrile and dimethylamine costs can pressure margins. New Asian capacity could also exceed near-term demand, creating price competition, especially for producers that lack integrated feedstock or differentiated purity grades.

Handling and product-purity requirements
DMAPA is a hazardous industrial intermediate requiring careful handling. Residual amines in downstream betaines can create sensitization concerns, so cosmetics customers increasingly emphasize analytical control, specifications and supplier qualification.

Future Outlook
Asia Pacific should remain the main production and demand center, with surfactants anchoring volume and epoxy applications contributing above-average growth. Supplier positioning will depend on feedstock integration, reliable logistics, high-purity grades and the pace at which new capacity is absorbed.

Competitive Landscape
BASF and Eastman Chemical are identified as integrated DMAPA producers, while Zhangjiagang Feixiang Chemical and Zhejiang Xinhua Chemical participate in Chinese production. Huntsman is relevant to downstream amine chemistry. Solvay, Evonik and Kao are better described as converters or customers for DMAPA-based surfactants rather than direct merchant DMAPA producers. No credible company-specific DMAPA revenue ranking is available.

Key Players
BASF; Eastman Chemical; Zhangjiagang Feixiang Chemical; Zhejiang Xinhua Chemical; Huntsman (downstream derivatives); Solvay (surfactants); Evonik (surfactants); Kao (surfactants)

Recent Developments

Oct. 16, 2025: BASF said the July start-up of expanded DMAPA production in Nanjing nearly doubled the site’s annual capacity and raised BASF’s global DMAPA capacity by more than 20% to approximately 85,000 metric tons.July 2025: As part of the same Nanjing project, BASF expanded polyetheramine capacity by about 25%. This is a related amine-chain investment, not an additional DMAPA plant.

Report Coverage
The study provides market estimates for 2025 and 2035, a 2026 interim estimate, analysis of the defined product and service scope, segment and geographic revenue shares, demand drivers, technology changes, competitive roles, constraints and recent dated developments. The reported CAGR and regional shares are based on Credence Research’s market model. Company announcements are contextual evidence and should not be interpreted as independent verification of the forecast.

Read the complete report and request a sample: https://www.credenceresearch.com/report/dimethylaminopropylamine-market 

Related Reports

https://www.credenceresearch.com/report/apac-infectious-enteritis-treatment-market 

https://www.credenceresearch.com/report/australia-digital-therapeutics-market 

https://www.credenceresearch.com/report/australia-corporate-education-and-upskilling-market 

https://www.credenceresearch.com/report/prescription-drugs-market 

https://www.credenceresearch.com/report/orthopedic-devices-market 

https://www.credenceresearch.com/report/parkinsons-disease-therapeutics-market 

https://www.credenceresearch.com/report/plasma-derived-therapy-market 

https://www.credenceresearch.com/report/over-the-counter-drugs-market 

https://www.credenceresearch.com/report/orphan-drugs-market 

https://www.credenceresearch.com/report/pediatric-drugs-market 

https://www.credenceresearch.com/report/pain-management-drugs-market 

https://www.credenceresearch.com/report/osteoporosis-drugs-market 

https://www.credenceresearch.com/report/patient-monitoring-devices-market 

https://www.credenceresearch.com/report/australia-drive-by-wire-market 

https://www.credenceresearch.com/report/australia-cold-chain-and-refrigerated-transport-market 

https://www.credenceresearch.com/report/australia-critical-illness-insurance-market 

https://www.credenceresearch.com/report/asia-pacific-lysosomal-acid-lipase-deficiency-lal-d-treatment-market 

https://www.credenceresearch.com/report/australia-eco-friendly-labels-market 

https://www.credenceresearch.com/report/apac-healthcare-digital-twins-market 

https://www.credenceresearch.com/report/australia-electric-vehicle-charger-operations-and-maintenance-services-market 

https://www.credenceresearch.com/report/australia-driveline-components-market 

About Us
Credence Research Inc. is a global market intelligence and consulting firm founded in 2015. It provides quantitative market research, competitive intelligence and strategic advisory services to businesses, investors and other organizations. Its research draws on primary and secondary information, industry interviews and structured market models.

The firm analyzes market size, growth drivers, segmentation, regional opportunities, supply chains and competitive positioning across industrial, technology, energy, health care and consumer markets. Its studies help clients evaluate strategic and investment decisions with documented assumptions and industry context.

Contact Us
Credence Research Inc. 
Tower C-1105, S 25, Akash Tower
Vishal Nagar, Pimple Nilakh, Haveli, Pune 411027, India 
USA: +1-888-600-6441 
sales@credenceresearch.com 
www.credenceresearch.com 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/dimethylaminopropylamine-market-to-reach-usd-731-9-million-by-2035-on-surfactant-and-epoxy-demand-credence-research-finds-302918151.html

Continue Reading

Technology

Misty Ventures and Aplicata Technologies Announce Strategic Partnership to Pursue Canadian Defence Opportunities

Published

on

By

Together, Aplicata and Misty Ventures will leverage their respective expertise, networks, and resources to support the commercialization of innovative technologies and help bring impactful solutions to government and public-sector markets.

SASKATOON, SK, Oct. 23, 2026 /PRNewswire-PRWeb/ — Misty Ventures, the economic development arm of Mistawasis Nêhiyawak, and Aplicata Technologies, a trusted leader in high-performance computing platforms for mission-critical defence applications, today announced they have signed a Memorandum of Understanding to explore a strategic partnership focused on pursuing and strengthening Canadian defence market opportunities.

“Partnering with Misty Ventures allows us to bring our capabilities to the Canadian defence market in a way that also creates lasting economic benefit for Mistawasis Nêhiyawak. We’re excited about the opportunity to build something meaningful together.” Mohammad Darwish, CEO of Aplicata.

Aplicata and Misty Ventures have agreed to form a Saskatchewan-based joint venture to develop and commercialize electronic warfare (EW), signals intelligence (SIGINT) and intelligence, surveillance and reconnaissance (ISR) technologies for Canadian defence.

The joint venture will deliver solutions across uncrewed aerial vehicles, aircraft, ground vehicles and naval vessels, providing the Canadian Armed Forces with a decisive operational advantage through advanced, mission-critical technology. It brings together Aplicata’s engineering, manufacturing and market expertise with Misty Ventures’ business development experience and its access to skilled talent and defence markets.

A guiding principle of the partnership is to build upon the strong business acumen, entrepreneurial capacity, and strategic vision of Mistawasis Nêhiyawak and its affiliated Indigenous communities. Through this partnership, Mistawasis Nêhiyawak seeks to leverage these strengths to contribute meaningfully to Canada’s defence priorities, supporting the development of sovereign capabilities, domestic innovation, and resilient Canadian supply chains. In addition to technology licensing, Aplicata intends to support the partnership through advanced knowledge and skills development, enabling Mistawasis Nêhiyawak to further expand its participation in Canada’s defence and security ecosystem and create lasting economic opportunity.

“This partnership reflects our commitment to building long-term, sustainable economic opportunities for Mistawasis Nêhiyawak and our broader community,” said Robert Daniels, Chief Executive Officer of Misty Ventures. “By combining our experience and market reach with Aplicata’s proven technology and market expertise, we believe we can create a defence sector business that delivers real value for Canada while creating meaningful opportunities for our people.”

“Aplicata brings a long history of innovation in advanced technologies for defence,” said Mohammad Darwish, Chief Executive Officer of Aplicata Technologies. “Partnering with Misty Ventures allows us to bring our capabilities to the Canadian defence market in a way that also creates lasting economic benefit for Mistawasis Nêhiyawak. We’re excited about the opportunity to build something meaningful together.”

About Misty Ventures

Since 2015, Misty Ventures has been the economic development entity of Mistawasis Nêhiyawak, growing through strategic partnerships across Saskatchewan’s construction, mining, oil and gas, and renewable energy sectors. Misty Ventures continues to pursue investments and collaborations aligned with its vision, mission, and values.

www.mistyventures.ca

About Aplicata Technologies

Aplicata is a trusted leader in high-performance computing platforms for mission-critical defence applications. We create innovative solutions engineered for performance and reliability, delivering results our customers can depend on. Rooted in a culture of collaboration and driven by a shared sense of purpose, we serve government and commercial organizations alike, pushing the boundaries of technology to enable new possibilities.

www.aplicata.com

Media Contact

Media Relations, Aplicata Technologies, 1 (844) 250-6300, media@aplicata.com, www.aplicata.com

View original content to download multimedia:https://www.prweb.com/releases/misty-ventures-and-aplicata-technologies-announce-strategic-partnership-to-pursue-canadian-defence-opportunities-302917752.html

SOURCE Aplicata Technologies

Continue Reading

Trending